News

  • 21 September 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Health Canada has approved its next generation rechargeable implantable neurostimulator (INS) for the Axonics r-SNM® System. 

  • 17 September 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today provides business update and announces its consolidated financial results for the six months ended June 30, 2020, prepared in accordance with IFRS. 

  • 16 September 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, Axonics CEO, has been named an Ernst & Young Entrepreneur of the Year 2020 Award finalist for Orange County. The Entrepreneur of the Year program honors entrepreneurial business leaders whose vision fosters innovation, growth and prosperity as they build and sustain successful businesses. 

  • 14 September 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today announced the enrollment of the first patient in the investigator-initiated Phase 2 clinical trial of setanaxib, the Company’s lead product candidate, in idiopathic pulmonary fibrosis (IPF). This study is conducted in accordance with the protocol approved by the U.S. Food and Drug Administration (FDA) and relevant Institutional review board (IRB).

  • 10 September 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has reported full 2-year clinical results from its ARTISAN-SNM pivotal study.